Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.

N D Wood, M Aitken, S Durston, S Harris, G R McClelland, S Sharp
{"title":"Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis.","authors":"N D Wood,&nbsp;M Aitken,&nbsp;S Durston,&nbsp;S Harris,&nbsp;G R McClelland,&nbsp;S Sharp","doi":"10.1007/978-3-0348-8857-8_8","DOIUrl":null,"url":null,"abstract":"<p><p>CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC0-infinity and Cmax. Administration of 10 mg CPA following food resulted in a delayed tmax, and a significant decrease in Cmax but not AUC0-infinity.</p>","PeriodicalId":7491,"journal":{"name":"Agents and actions. Supplements","volume":"49 ","pages":"49-55"},"PeriodicalIF":0.0000,"publicationDate":"1998-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Agents and actions. Supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-0348-8857-8_8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 7

Abstract

CPA was well tolerated at all dose levels (10-150 mg) following single oral dose administration to healthy male volunteers. There was no relationship between the intensity, duration and number of adverse events reported and the dose of CPA. There was a dose-related increase in exposure as measured by AUC0-infinity and Cmax. Administration of 10 mg CPA following food resulted in a delayed tmax, and a significant decrease in Cmax but not AUC0-infinity.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
软骨保护剂(CPA) Ro 32-3555,一种治疗类风湿关节炎的新型基质金属蛋白酶抑制剂。
健康男性志愿者单次口服给药后,CPA在所有剂量水平(10- 150mg)均具有良好的耐受性。报告的不良事件的强度、持续时间和数量与CPA的剂量没有关系。通过AUC0-infinity和Cmax测量,暴露量有剂量相关的增加。进食后给予10 mg CPA可导致tmax延迟,Cmax显著降低,但auc0无无穷大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Cartilage protective agent (CPA) Ro 32-3555, a new matrix metalloproteinase inhibitor for the treatment of rheumatoid arthritis. Immunomodulation of Crohn's disease by interleukin-10. Ro 45-2081, a TNF receptor fusion protein, prevents inflammatory responses in the airways. Targets in cytokine activation. ICE family proteases in inflammation and apoptosis.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1